Blue Emu generates awareness with Arthritis Foundation
The Arthritis Foundation partnered with Blue Emu Maximum Arthritis Pain Relief Cream, NFI Consumer Products announced Monday.
“Since the launch of our Blue Emu Maximum Arthritis SKU, we have received many letters praising the help this product provides to customers with Arthritis,” Benjamin Blessing, executive vice president sales and marketing for the Bristol, Tenn.-based company, said. “It just made sense that we partner with the Arthritis Foundation so we could help raise awareness for the pain many of our Blue Emu Maximum Arthritis customers deal with every day.”
The partnership continues through 2018 and features a specially marked Blue Emu Maximum Arthritis tube with the Arthritis Foundation logo. By partnering with the Arthritis Foundation, Blue Emu will help raise awareness about arthritis and support the Arthritis Foundation’s mission to help the more than 54 million Americans chart a winning course and make each day another stride towards a cure.
“At the Arthritis Foundation, we’re committed to helping people with arthritis live their best life, which includes managing and relieving their pain,” Ann McNamara, the Arthritis Foundation senior vice president of revenue strategy, said. “This new partnership with Blue Emu underscores our belief that people with arthritis should have a variety of treatment options when deciding how they control their pain.”
Blue Emu will ship the specially marked Maximum Arthritis product beginning in February 2018. The product is the No. 5 branded external analgesic, according to the latest IRI sales data, and it’s growing fast. Sales for the 52 weeks ended Dec. 3 totaled $42 million across total U.S. multi-outlets, representing growth of 22.3% . That outpaces growth of 17.8% for the entire category, which reached $723.6 million in sales in that period.
And that growth is coming from a premium pain relief SKU. Blue Emu sells at a 2.3 x premium to the average pricepoint of $6.71 for the category with an average price per unit sold of $15.38. NFI sold 2.7 million units in the same period noted above, representing growth of 22.2%.
Oilogic expands aromatherapy portfolio by four
After starting in baby care products, Addison, Texas-based Oilogic will expand its product line to carry a range of adult and kid products in winter 2018.
For example ,the Oilogic Adult Sinus & Allergy Essential Oil Roll-On naturally comforts and clears the senses during allergy season with a blend of Essential Oils including lavender oil, lemon oil and peppermint oil. Roll on Oilogic Sinus & Allergy Essential Oil Blend to the back of the neck, chest and wrists, and breathe deeply, the company suggested.
Similarly, the Oilogic Adult Cough & Cold Essential Oil Roll-On naturally soothes discomfort and provides a clearing aroma.
Meanwhile, Oilogic Kids Cold & Cough Essential Oil Roll-On is used to naturally soothe stuffy nose and cough symptoms with a blend of Essential Oils. This blend is diluted appropriately with Jojoba Oil and Castor Oil to safely apply directly to the child’s skin, safe for children 2 years and up. Parents simply roll the oil on their child’s chest, back of neck and bottom of feet to continue the aromatherapy experience. Also, there is the Oilogic Kids Nighttime & Sleep Essential Oil Roll-On.
“I’ve been that mom who’s sick with sick kids at the pharmacy just waiting for our prescriptions,” Oilogic co-founder Jordan Morrow, said. “Now people can grab one of our products and instantly soothe their symptoms while they wait at the pharmacy.”
Flu incidence crests at 6.6%, highest in this decade
The good news to come out of Friday morning’s CDC Flu View news conference is that we are about halfway through the season. The bad news is we still have half a season to go, and this season has been the worst in flu incidence since the 2009 H1N1 pandemic.
That year, flu incidence reached a peak of 7.7%. For the week ended Jan. 20, flu incidence crested at 6.6% nationwide, though there were signs that flu incidence rates were declining in some parts of the country.
“It has been a tough flu season so far this year,” Dan Jernigan, director of the influenza division in CDC’s National Center for Immunization and Respiratory Diseases, said. “This rapid increase in cases that we’ve been seeing is after the winter holidays and it is among all ages but it is higher among children. So it looks like a big part of the later January activity is flu transmission from kids returning to school.”
And it’s not abating. “While flu activity is beginning to go down in some parts of the country, it remains high for most of the U.S. with some areas still rising. Most people with influenza are being infected with the H3N2 influenza virus. In seasons where H3N2 is the main cause of influenza, we see more cases, more visits to the doctor, more hospitalizations and more deaths, especially among older people,” Jernigan said. “We’ve experienced two notable characteristics of flu this season. The first is that flu activity became widespread in almost all states and jurisdictions at the same time. The second notable characteristic is that flu activity has now stayed at the same level at the national level for three weeks in a row with 49 states reporting widespread activity each week for three weeks.”
The 2017/2018 influenza season is nine weeks old. The average season over the past five years is 16 weeks, with the longest season in the past five years extending 20 weeks. “In past seasons that are like this one, we have estimated that by the end of the season, 34 million Americans had gotten the flu,” Jernigan said.
“The flu season is continuing to be challenging and flu has been intense across the United States,” Brenda Fitzgerald, director CDC , said. “Remember, it’s not too late to get a flu shot for yourself and for your child.”